Transforming Traditional Medical Affairs
The 2nd Gene Therapy Medical Affairs Summit is dedicated to exploring the pivotal internal and external role Medical Affairs plays in delivering gene therapies to patients.
Whilst Gene Therapies are set to transform treatment paradigms, their complex nature and high price tag presents unique challenges. Learn how the global leaders of the gene therapy world are transforming the traditional role of medical affairs, from reactive to proactive strategic partners to launch gene therapy products more efficiently and effectively than ever before.
Join Orchard Therapeutics, PTC Therapeutics, Sanofi Genzyme and others as we start to define both the role and value of Medical Affairs from early development of gene therapies right the way to a launch environment.
Whether it is learning how to educate and upskill cross-functional teams or tailoring engagement strategies with external HCPs, regulators and patient advocates, join us to determine how best to create a cohesive and streamlined launch strategy specifically for gene therapy products.
We will delve into the unique challenge encountered when working with gene therapies, from adapting to the clinical realities of the rare disease space to handling long-term follow up and post-launch regulatory scrutiny, equipping you with the insights required to for a successful and patient-centric launch.
2022 Expert Speakers Included:
Ian Winburn
Vice President, Global Medical Team Lead, Haemophilia, Endocrine In-born Errors of Metabolism and Transplantation
Pfizer
Tara Moroz
Director, Gene Therapy Platform and Cross Portfolio, Rare Diseases, Global Medical Affairs
Pfizer
2022 Attendees Included:
Hear What Our Audience Say:
“Great experience where I learned a lot from experts who were sharing their drive and best practices in the gene therapy MA environment.”
Wim Weyenberg, Head of Medical Affairs & Operations, UCB
“Enriching and inspiring experience, an highly effective and interactive digital event with thought leaders sharing insights, experiences and vision on the key strategic role of Medical Affairs in delivering gene therapy to patients.
Eleonora Russo, Director Rare Disease Medical, Pfizer
“We really enjoyed the partnership opportunity and look forward to see what lasting relationships might develop from the conference. It was great to be able to share our perspective with leaders in MA.
Crecia Magee, President & Principal Talent Executive, PharmaFinders
2022 Partners:
2022 Media Partners:
Other Events in the Gene Therapy Series:
